Brian Abrahams
Stock Analyst at RBC Capital
(2.18)
# 2,614
Out of 4,784 analysts
447
Total ratings
40.25%
Success rate
-6.33%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $67 | $39.86 | +68.09% | 1 | Mar 18, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $21 | $7.74 | +171.32% | 1 | Mar 10, 2025 | |
| GHRS GH Research | Initiates: Outperform | $31 | $11.06 | +180.29% | 1 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Sector Perform | $4 → $3 | $1.47 | +104.08% | 13 | Mar 4, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Sector Perform | $4 | $1.03 | +288.35% | 6 | Mar 4, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $165 → $161 | $70.41 | +128.66% | 32 | Feb 27, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $10 → $11 | $7.86 | +39.95% | 16 | Feb 25, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $24 → $20 | $13.14 | +52.21% | 10 | Feb 21, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $407 → $408 | $492.69 | -17.19% | 50 | Feb 20, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Outperform | $45 | $4.16 | +981.73% | 11 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $63 | $54.24 | +16.15% | 18 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $231 → $225 | $138.37 | +62.61% | 34 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $84 → $90 | $111.79 | -19.49% | 31 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $70 → $68 | $60.60 | +12.21% | 20 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $154 → $148 | $113.16 | +30.79% | 17 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $118.53 | +20.64% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $21.76 | +83.82% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $108 → $132 | $131.81 | +0.14% | 19 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.24 | +20.97% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $7.07 | +338.47% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $1.5 | $0.52 | +190.53% | 5 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $48 → $2 | $1.18 | +69.49% | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Perform | $4 | $8.28 | -51.69% | 21 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,260 → $1,215 | $637.36 | +90.63% | 30 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $25.46 | +17.83% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $82 | $5.52 | +1,385.51% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $34.26 | +60.54% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $8.08 | +48.51% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.19 | +255.41% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $5.71 | +162.70% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.47 | +512.24% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $44.61 | -26.03% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $37.82 | - | 4 | Dec 4, 2017 |
MoonLake Immunotherapeutics
Mar 18, 2025
Initiates: Outperform
Price Target: $67
Current: $39.86
Upside: +68.09%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Outperform
Price Target: $21
Current: $7.74
Upside: +171.32%
GH Research
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $11.06
Upside: +180.29%
Pliant Therapeutics
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.47
Upside: +104.08%
Neumora Therapeutics
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $1.03
Upside: +288.35%
Sarepta Therapeutics
Feb 27, 2025
Maintains: Outperform
Price Target: $165 → $161
Current: $70.41
Upside: +128.66%
BioCryst Pharmaceuticals
Feb 25, 2025
Reiterates: Outperform
Price Target: $10 → $11
Current: $7.86
Upside: +39.95%
Prothena Corporation
Feb 21, 2025
Maintains: Sector Perform
Price Target: $24 → $20
Current: $13.14
Upside: +52.21%
Vertex Pharmaceuticals
Feb 20, 2025
Maintains: Sector Perform
Price Target: $407 → $408
Current: $492.69
Upside: -17.19%
Karyopharm Therapeutics
Feb 20, 2025
Reiterates: Outperform
Price Target: $45
Current: $4.16
Upside: +981.73%
Feb 18, 2025
Maintains: Outperform
Price Target: $60 → $63
Current: $54.24
Upside: +16.15%
Feb 13, 2025
Maintains: Outperform
Price Target: $231 → $225
Current: $138.37
Upside: +62.61%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $84 → $90
Current: $111.79
Upside: -19.49%
Feb 11, 2025
Maintains: Sector Perform
Price Target: $70 → $68
Current: $60.60
Upside: +12.21%
Feb 7, 2025
Maintains: Sector Perform
Price Target: $154 → $148
Current: $113.16
Upside: +30.79%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $118.53
Upside: +20.64%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $21.76
Upside: +83.82%
Jan 22, 2025
Downgrades: Sector Perform
Price Target: $108 → $132
Current: $131.81
Upside: +0.14%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.24
Upside: +20.97%
Jan 9, 2025
Reiterates: Outperform
Price Target: $31
Current: $7.07
Upside: +338.47%
Dec 20, 2024
Maintains: Sector Perform
Price Target: $4 → $1.5
Current: $0.52
Upside: +190.53%
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $1.18
Upside: +69.49%
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $8.28
Upside: -51.69%
Nov 1, 2024
Maintains: Outperform
Price Target: $1,260 → $1,215
Current: $637.36
Upside: +90.63%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $25.46
Upside: +17.83%
Sep 20, 2024
Reiterates: Outperform
Price Target: $82
Current: $5.52
Upside: +1,385.51%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $34.26
Upside: +60.54%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $8.08
Upside: +48.51%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $6.19
Upside: +255.41%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $5.71
Upside: +162.70%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.47
Upside: +512.24%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $44.61
Upside: -26.03%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $37.82
Upside: -